278 related articles for article (PubMed ID: 30975979)
21. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
23. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
24. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract][Full Text] [Related]
26. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
27. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider M; Eichner R; Stroh J; Morath V; Kuisl A; Zecha J; Lawatscheck J; Baek K; Garz AK; Rudelius M; Deuschle FC; Keller U; Lemeer S; Verbeek M; Götze KS; Skerra A; Weber WA; Buchner J; Schulman BA; Kuster B; Fernández-Sáiz V; Bassermann F
Mol Cell; 2021 Mar; 81(6):1170-1186.e10. PubMed ID: 33571422
[TBL] [Abstract][Full Text] [Related]
28. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
Beedie SL; Huang PA; Harris EM; Strope JD; Mahony C; Chau CH; Vargesson N; Figg WD
FASEB J; 2020 Sep; 34(9):11395-11404. PubMed ID: 32677118
[TBL] [Abstract][Full Text] [Related]
29. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4
An J; Ponthier CM; Sack R; Seebacher J; Stadler MB; Donovan KA; Fischer ES
Nat Commun; 2017 May; 8():15398. PubMed ID: 28530236
[TBL] [Abstract][Full Text] [Related]
30. MCM5 as a target of BET inhibitors in thyroid cancer cells.
Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
[TBL] [Abstract][Full Text] [Related]
31. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
32. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Hansen JD; Correa M; Nagy MA; Alexander M; Plantevin V; Grant V; Whitefield B; Huang D; Kercher T; Harris R; Narla RK; Leisten J; Tang Y; Moghaddam M; Ebinger K; Piccotti J; Havens CG; Cathers B; Carmichael J; Daniel T; Vessey R; Hamann LG; Leftheris K; Mendy D; Baculi F; LeBrun LA; Khambatta G; Lopez-Girona A
J Med Chem; 2020 Jul; 63(13):6648-6676. PubMed ID: 32130004
[TBL] [Abstract][Full Text] [Related]
33. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
[TBL] [Abstract][Full Text] [Related]
34. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
[TBL] [Abstract][Full Text] [Related]
35. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
[TBL] [Abstract][Full Text] [Related]
36. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
38. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
40. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Song Y; Park PMC; Wu L; Ray A; Picaud S; Li D; Wimalasena VK; Du T; Filippakopoulos P; Anderson KC; Qi J; Chauhan D
Leukemia; 2019 Nov; 33(11):2685-2694. PubMed ID: 30962579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
